Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of [14C] ASN002 in Healthy Male Subjects
NCT03641573Phase 1Completed
- Sponsor
- Asana BioSciences, LLC
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gusacitinib in atopic dermatitis (AD) and chronic hand eczema (CHE), sponsored by Asana BioSciences, LLC. Primary endpoints: Maximum observed plasma concentration at 216 hours, Time to Cmax at 216 hours and 6 more. Started Oct 2018; status: completed.
02
Drugs
gusacitinib
03
Conditions
atopic dermatitis (AD)chronic hand eczema (CHE)
Beyond the preview
Go deeper on NCT03641573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641573.